Street Calls of the Week
Investing.com - TD Cowen has reiterated its Buy rating on Cellebrite (NASDAQ:CLBT) with a price target of $25.00, following investor meetings with the company’s management team. The digital intelligence company, currently trading at $17.55 with a market cap of $4.32 billion, has analyst targets ranging from $18 to $28, according to InvestingPro data.
The meetings included Cellebrite CEO Thomas Hogan, CFO David Barter, and VP IR Andrew Kramer, where they discussed the company’s current business momentum and growth initiatives.
TD Cowen noted that Cellebrite’s Inseyets product is "ramping quickly" while Guardian is gaining momentum in the market, indicating strong product performance across the company’s portfolio.
The firm highlighted that FedRAMP certification is expected to drive growth in Cellebrite’s Federal business segment, expanding the company’s government sector opportunities.
TD Cowen also pointed to Cellebrite’s acquisition of Corellium as a strategic move that should strengthen the company’s product portfolio, with the analyst expressing confidence that Cellebrite is "positioned to deliver sustained Rule-of-45+ performance."
In other recent news, Cellebrite reported its financial results for the second quarter of 2025, surpassing earnings expectations. The company’s earnings per share (EPS) were $0.08, exceeding analyst forecasts of $0.0771 by 3.76%. Although there was a slight shortfall in revenue, the overall performance was well-received by investors. The positive reaction highlights investor confidence in Cellebrite’s strategic direction. These developments come amid ongoing interest in the company’s growth prospects. Analysts have noted the company’s ability to outperform earnings expectations, which could influence future assessments. This update adds to the recent developments surrounding Cellebrite’s financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.